Advanced search
Publication Cover
Journal of Medical Economics Volume 19, 2016 - Issue 8
Submit an article Journal homepage
1,006
Views
14
CrossRef citations to date
0
Altmetric
Hepatology

Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US

Sammy SaabUCLA, Pfleger Liver Institute, Los Angeles, CA, USA;
,
Hélène PariséMedicus Economics LLC, Milton, MA, USA;
,
Suchin VirabhakMedicus Economics LLC, Milton, MA, USA;
,
Alice WangAbbVie, Health Economics and Outcomes Research, Mettawa, IL, USACorrespondence[email protected]
,
Steven E. MarxAbbVie, Health Economics and Outcomes Research, Mettawa, IL, USA
,
Yuri Sanchez GonzalezAbbVie, Health Economics and Outcomes Research, Mettawa, IL, USA
,
Derek MisurskiAbbVie, Health Economics and Outcomes Research, Mettawa, IL, USA
&
Scott JohnsonMedicus Economics LLC, Milton, MA, USA;
show all
Pages 795-805 | Received 07 Mar 2016, Accepted 05 Apr 2016, Published online: 24 Apr 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Jaume Puig-Junoy, Natàlia Pascual-Argente, Lluc Puig-Codina, Laura Planellas & Míriam Solozabal. (2018) Cost-utility analysis of second-generation direct-acting antivirals for hepatitis C: a systematic review. Expert Review of Gastroenterology & Hepatology 12:12, pages 1251-1263.
Read now
Allister Sebastian Lee, Mieke L van Driel & Darrell HG Crawford. (2017) The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. ClinicoEconomics and Outcomes Research 9, pages 595-607.
Read now
Suchin Virabhak, Kikuo Yasui, Kiyotaka Yamazaki, Scott Johnson, Dominic Mitchell, Cammy Yuen, Jennifer C. Samp & Ataru Igarashi. (2016) Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan. Journal of Medical Economics 19:12, pages 1144-1156.
Read now
Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Ivana Filipovic, Jennifer C. Samp & Derek Misurski. (2016) Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. Journal of Medical Economics 19:10, pages 983-994.
Read now

Articles from other publishers (10)

R. A. Yakhina, I. A. Lakman, D. A. Valishin & R. Kh. Bakhitova. (2022) Economic burden of chronic viral hepatitis C. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology 14:4, pages 523-536.
Crossref
Jeffrey V. Lazarus, Juan M. Pericàs & Kristina L. Hetherington. 2021. Hepatitis C: Epidemiology, Prevention and Elimination. Hepatitis C: Epidemiology, Prevention and Elimination 247 270 .
Moosa Tatar, Susana W. Keeshin, Mark Mailliard & Fernando A. Wilson. (2020) Cost-effectiveness of Universal and Targeted Hepatitis C Virus Screening in the United States. JAMA Network Open 3:9, pages e2015756.
Crossref
T. Joseph MattinglyIIII, Julia F. Slejko, Eberechukwu Onukwugha, Eleanor M. Perfetto, Shyamasundaran Kottilil & C. Daniel Mullins. (2019) Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis. PharmacoEconomics 38:2, pages 233-242.
Crossref
László Szilberhorn, Zoltán Kaló & Tamás Ágh. (2018) Cost-Effectiveness of Second-generation Direct-acting Antiviral Agents in Chronic HCV Infection: A Systematic Literature Review. Antiviral Therapy 24:4, pages 247-259.
Crossref
Asrul Akmal Shafie, Muhammad Radzi Abu Hassan, Norazila Abdul Ghani, Beng Hoong Chew & Nor Syahireen Mohammed. (2018) Cost analysis of chronic hepatitis C virus management in a Malaysia tertiary hospital. Journal of Pharmaceutical Health Services Research 9:2, pages 141-144.
Crossref
Lauren E. Cipriano & Jeremy D. Goldhaber-Fiebert. (2018) Population Health and Cost-Effectiveness Implications of a “Treat All” Recommendation for HCV: A Review of the Model-Based Evidence. MDM Policy & Practice 3:1, pages 238146831877663.
Crossref
T. He, M. A. Lopez-Olivo, C. Hur & J. Chhatwal. (2017) Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6. Alimentary Pharmacology & Therapeutics 46:8, pages 711-721.
Crossref
Juan Turnes, Raquel Domínguez-Hernández & Miguel Ángel Casado. (2017) Análisis coste-efectividad de dos estrategias de tratamiento para la hepatitis C crónica: antes y después del acceso a los agentes antivirales de acción directa en España. Gastroenterología y Hepatología 40:7, pages 433-446.
Crossref
Juan Turnes, Raquel Domínguez-Hernández & Miguel Ángel Casado. (2017) Cost-effectiveness analysis of two treatment strategies for chronic hepatitis C before and after access to direct-acting antivirals in Spain. Gastroenterología y Hepatología (English Edition) 40:7, pages 433-446.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.